Urs Häfeli PhD
Professor Emeritus
Dr. Urs Häfeli completed a bachelor of science in pharmacy at the Federal Institute of Technology (Zurich, Switzerland) and a doctor of philosophy in pharmacy at Paul Scherrer Institute/Federal Institute of Technology in Zurich. After a postdoc at Harvard’s Joint Center of Radiation Therapy in Boston, MA, USA, he worked for 11 years as a scientist in the Radiation Oncology Department of the Cleveland Clinic in Cleveland, OH, USA. From 2004 to 2024, he then worked as a professor in Nanomedicines, Radiopharmaceuticals and Drug Delivery at UBC’s Faculty of Pharmaceutical Sciences.
Research in the Häfeli Laboratory is primarily directed at the development of diagnostic and therapeutic radiopharmaceuticals to be used in different nuclear medicine procedures (SPECT, PET, CT, MRI, optical imaging). The lab also exploits nanotechnology and microtechnology for different drug delivery applications, including the development of painless microneedles and the use of microfluidics for the preparation of monosized microspheres and nanoparticles. Under the guidance of Research Associate Dr. Kathy Saatchi, the Häfeli Laboratory has a strong chemistry base that encompasses organic, coordination and polymer chemistry. Using these tools, Dr. Häfeli’s research includes the entire spectrum of drug research from the synthesis and radiolabelling of new molecules; the preparation of drug delivery carriers such as nanoparticles, microspheres, antibodies, and polymers; the careful evaluation of drug delivery systems in vitro and in toxicology experiments; and finally, efficacy testing in different in vivo models using many different imaging modalities.
For more details, see the Häfeli Lab website.
A few recent publications are shown below. To see a complete list of our lab publications, please see https://www.magneticmicrosphere.com/hafeli_lab/page-publications.
Esposito TVF, Blackadar C, Wu L, Rodriguez-Rodriguez C, Haney EF, Pletzer D, Saatchi K, Hancock REW, Hafeli UO (2024). Biodistribution of Native and Nanoformulated Innate Defense Regulator (IDR) Peptide 1002. Mol Pharm 21, 2751-2766
Bohrmann L, Poulie CBM, Rodriguez-Rodriguez C, Karagiozov S, Saatchi K, Herth MM, Hafeli UO (2024). Development of a 99mTc-Labeled Tetrazine for Pretargeted SPECT Imaging Using an Alendronic Acid-Based Bone Targeting Model. PLOS ONE 19(4), e0300466.
Charles L, Sekar S, Osooly M, Javed S, Williams KC, Welch I, Barta I, Saatchi K, Häfeli UO (2024). Development of an Immunosuppressed Orthotopic Hepatocellular Carcinoma Rat Model for the Evaluation of Chemo- and Radioembolization Therapies. Europ J Pharm Biopharm 196, 114180
Li N, Fei P, Tous C, Rezaei Adariani M, Hautot M-L, Ouedraogo I, Hadjadj A, Dimov IP, Zhang Q, Lessard S, Nosrati Z, Ng CN, Saatchi K, Häfeli UO, Tremblay C, Kadoury S, Tang A, Martel S, Soulez G (2024). Human-scale navigation of magnetic microrobots in hepatic arteries. Science Robotics 9, eadh8702
Saatchi K, Benard F, Hundal N, Grimes J, Shcherbinin S, Pourghiasian M, Brooks DE, Celler A, Häfeli UO (2023). Preclinical PET Imaging and Toxicity Study of a 68Ga-Functionalized Polymeric Cardiac Blood Pool Agent. Pharmaceutics 15, 767
Innovator award of the Cleveland Clinic Foundation, Cleveland, Ohio, USA (2004)
Pharmaceutical Sciences Award for Excellence in Translational Graduate Teaching, UBC (2014 and 2016)